Extracellular matrix

Extracellular matrix
Twooars · Public domain · source
Name	Extracellular matrix
Latin	matrix extracellularis
Components	Collagens; elastin; fibronectin; laminins; proteoglycans; hyaluronan

Extracellular matrix

The extracellular matrix is a complex, non-cellular network of macromolecules that provides structural and biochemical support to surrounding cells. It integrates mechanical properties with biochemical signaling in tissues, mediating processes from embryogenesis to wound healing and disease. Major contributors to modern understanding include researchers associated with institutions such as the Max Planck Society, Harvard University, University of Cambridge, Massachusetts Institute of Technology, and historical figures studied at the Royal Society.

Composition and molecular components

The molecular composition includes a diversity of proteins and polysaccharides whose discovery and characterization involved teams at Rockefeller University, Stanford University, University of California, San Francisco, and biotechnology firms like Genentech. Prominent structural proteins include multiple types of collagens first cataloged in studies linked to Nobel Prize–winning laboratories, elastin characterized in work connected to Johns Hopkins University, and glycoproteins such as fibronectin and laminins described in research from Cold Spring Harbor Laboratory. Proteoglycans and glycosaminoglycans such as hyaluronan were elucidated by groups at Karolinska Institutet and University of Oxford. Matrix metalloproteinases (MMPs), a family of proteases produced by stromal cells and immune cells investigated at National Institutes of Health and pharmaceutical companies like Pfizer, regulate ECM turnover. Adhesion receptors such as integrins, discovered in collaborations involving University of California, Berkeley and University of Toronto, link cells to ECM ligands and cooperate with co-receptors identified in studies at Imperial College London.

Structure and organization

ECM organization ranges from highly ordered basement membranes first described in pathology departments associated with Mayo Clinic and Cleveland Clinic to loose interstitial matrices modeled by tissue engineers at ETH Zurich and MIT Media Lab. Basement membranes contain laminin networks and type IV collagen arranged with nidogen and perlecan, a stoichiometry inferred from biophysical work at Lawrence Berkeley National Laboratory. Interstitial ECM displays fibrillar collagens (types I and III), elastin fibers, and cross-linking enzymes like lysyl oxidase characterized by teams at University of Pennsylvania and University College London. Tissue-specific ECM architecture is central to organs studied at Karolinska University Hospital, including cartilage matrices with aggrecan prominent in research from Hospital for Special Surgery. Three-dimensional ECM models have been recapitulated in organoid systems developed at Broad Institute and Wellcome Trust Sanger Institute.

Functions and biological roles

ECM provides tensile strength and elasticity, functions elucidated in biomechanical studies at California Institute of Technology and ETH Zurich, and sequesters growth factors in gradients investigated by developmental biologists at European Molecular Biology Laboratory and Howard Hughes Medical Institute. In morphogenesis, ECM-mediated cues direct axis formation and branching morphogenesis analyzed in laboratories at Princeton University and University of Chicago. ECM modulates immune cell trafficking and inflammatory responses mapped by researchers at Institut Pasteur and Fred Hutchinson Cancer Center. In the nervous system, perineuronal nets and ECM remodeling influence plasticity in studies from Salk Institute and McGill University.

Development, remodeling, and repair

ECM composition changes dynamically during embryogenesis, processes dissected by teams at Max Planck Institute for Molecular Cell Biology and Genetics and Stowers Institute for Medical Research. Remodeling during wound healing engages fibroblasts, myofibroblasts, and macrophages whose roles were defined in clinical research at Mount Sinai Hospital and Mayo Clinic Hospital. Matrix turnover involves MMPs, ADAMTS proteases, and tissue inhibitors of metalloproteinases (TIMPs) characterized in translational programs at National Cancer Institute and European Research Council–funded consortia. Fibrosis and scar formation driven by persistent ECM deposition have been modeled in preclinical studies at Scripps Research and therapeutic approaches developed by biotechnology startups in Cambridge, Massachusetts and Cambridge, UK.

Interactions with cells and signaling

Cell–ECM interactions are mediated by integrin signaling hubs that connect to cytoskeletal regulators and focal adhesion complexes investigated in cell biology labs at Yale University and University of California, San Diego. ECM-bound growth factors such as transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) modulate pathways studied in contexts of oncology at Memorial Sloan Kettering Cancer Center and angiogenesis research at Duke University. Mechanotransduction through ECM stiffness alters stem cell fate decisions in studies pioneered at University of Pennsylvania and Stanford University School of Medicine. Crosstalk with signaling networks involving Wnt, Notch, and Hippo pathways emerged from collaborative projects at Wellcome Trust and National Institute for Health Research centers.

Pathology and clinical significance

ECM dysregulation underlies diseases including fibrosis, where clinical trials have been conducted at Cleveland Clinic and Johns Hopkins Medicine, and cancer, where tumor stroma remodeling affects metastasis studied extensively at Dana-Farber Cancer Institute and The Institute of Cancer Research. Genetic disorders of ECM components—such as Ehlers–Danlos syndrome, Marfan syndrome, and osteogenesis imperfecta—were characterized by clinical genetics units at Great Ormond Street Hospital, Boston Children's Hospital, and consortia connected to EuroGentest. Biomaterials and regenerative medicine strategies to replace or mimic ECM have been advanced by research groups at Wyss Institute and companies like Medtronic and Boston Scientific. Diagnostic imaging of ECM alterations uses modalities refined at Mayo Clinic and Massachusetts General Hospital, and anti-fibrotic or matrix-targeting therapeutics are in trials sponsored by organizations including European Medicines Agency and U.S. Food and Drug Administration.

Category:Cell biology